Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew N Billin

Showing results (11-20 of 55) with videos related to

Pageof 6
Sort By:
Carcinogenesis|September 26, 2007
Ligand activation of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) and inhibition of cyclooxygenase 2 (COX2) attenuate colon carcinogenesis through independent signaling mechanismsHolly E Hollingshead, Michael G Borland, Andrew N Billin, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 7, 2008
Glucose sensing by MondoA:Mlx complexes: a role for hexokinases and direct regulation of thioredoxin-interacting protein expressionCarrie A Stoltzman, Christopher W Peterson, Kevin T Breen, et al.
Stem Cell Reports|July 24, 2018
The AMPK/p27<sup>Kip1</sup> Axis Regulates Autophagy/Apoptosis Decisions in Aged Skeletal Muscle Stem CellsJames P White, Andrew N Billin, Milton E Campbell, et al.
Clinical and Translational Science|December 27, 2022
Pharmacokinetics, pharmacodynamics, safety and tolerability of cilofexor, a novel nonsteroidal Farnesoid X receptor agonist, in healthy volunteersIslam R Younis, Brian J Kirby, Andrew N Billin, et al.
Molecular Endocrinology (Baltimore, Md.)|June 21, 2003
Helix 1/8 interactions influence the activity of nuclear receptor ligand-binding domainsJason A Holt, Thomas G Consler, Shawn P Williams, et al.
Cellular Signalling|January 27, 2007
Ligand activation of peroxisome proliferator-activated receptor-beta/delta(PPARbeta/delta) inhibits cell growth of human N/TERT-1 keratinocytesAndrew D Burdick, Moses T Bility, Elizabeth E Girroir, et al.
Digestive Diseases and Sciences|April 4, 2007
PPARbeta/delta protects against experimental colitis through a ligand-independent mechanismHolly E Hollingshead, Keiichirou Morimura, Masahiro Adachi, et al.
Journal of Clinical Pharmacology|May 2, 2023
Effect of Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor AgonistIslam R Younis, Chia-Hsiang Hsueh, Cara Nelson, et al.
Cancer Research|April 19, 2006
Ligand activation of peroxisome proliferator-activated receptor beta inhibits colon carcinogenesisHolly E Marin, Marjorie A Peraza, Andrew N Billin, et al.
Alimentary Pharmacology & Therapeutics|March 30, 2026
Review Article: Targeting Peroxisome Proliferator-Activated Receptors in Primary Biliary CholangitisJörn M Schattenberg, Jesus M Banales, Gideon Hirschfield, et al.
Pageof 6

Showing results (11-20 of 55) with videos related to

Sort By:
Pageof 6
Carcinogenesis|September 26, 2007
Ligand activation of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) and inhibition of cyclooxygenase 2 (COX2) attenuate colon carcinogenesis through independent signaling mechanismsHolly E Hollingshead, Michael G Borland, Andrew N Billin, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 7, 2008
Glucose sensing by MondoA:Mlx complexes: a role for hexokinases and direct regulation of thioredoxin-interacting protein expressionCarrie A Stoltzman, Christopher W Peterson, Kevin T Breen, et al.
Stem Cell Reports|July 24, 2018
The AMPK/p27<sup>Kip1</sup> Axis Regulates Autophagy/Apoptosis Decisions in Aged Skeletal Muscle Stem CellsJames P White, Andrew N Billin, Milton E Campbell, et al.
Clinical and Translational Science|December 27, 2022
Pharmacokinetics, pharmacodynamics, safety and tolerability of cilofexor, a novel nonsteroidal Farnesoid X receptor agonist, in healthy volunteersIslam R Younis, Brian J Kirby, Andrew N Billin, et al.
Molecular Endocrinology (Baltimore, Md.)|June 21, 2003
Helix 1/8 interactions influence the activity of nuclear receptor ligand-binding domainsJason A Holt, Thomas G Consler, Shawn P Williams, et al.
Cellular Signalling|January 27, 2007
Ligand activation of peroxisome proliferator-activated receptor-beta/delta(PPARbeta/delta) inhibits cell growth of human N/TERT-1 keratinocytesAndrew D Burdick, Moses T Bility, Elizabeth E Girroir, et al.
Digestive Diseases and Sciences|April 4, 2007
PPARbeta/delta protects against experimental colitis through a ligand-independent mechanismHolly E Hollingshead, Keiichirou Morimura, Masahiro Adachi, et al.
Journal of Clinical Pharmacology|May 2, 2023
Effect of Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor AgonistIslam R Younis, Chia-Hsiang Hsueh, Cara Nelson, et al.
Cancer Research|April 19, 2006
Ligand activation of peroxisome proliferator-activated receptor beta inhibits colon carcinogenesisHolly E Marin, Marjorie A Peraza, Andrew N Billin, et al.
Alimentary Pharmacology & Therapeutics|March 30, 2026
Review Article: Targeting Peroxisome Proliferator-Activated Receptors in Primary Biliary CholangitisJörn M Schattenberg, Jesus M Banales, Gideon Hirschfield, et al.
Pageof 6